All panels called the same variants, with the exception of 3 cases, for which SureSeqTM AML Panel did not call two FLT3-ITD variants p.Phe594_Arg595ins12, p.Tyr589_Phe590ins12 (patient 7 and 16) and SureSeqTM Core MPN Panel did not called one CALR p.Leu367Thrfs*46 variant (patient 14). This evidence concerns the gene FLT3 and myeloproliferative neoplasm.